Trial Profile
A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trodusquemine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 15 May 2018 Status changed from suspended to discontinued due to lack of interest by sponsor
- 15 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.